Treatment of intermediate and advanced stage XXXX with modified baseline BEACOPP regimen: a Hellenic Co-operative Oncology Group Study.

@entity632 @entity1 @entity4289 @entity4174 @entity137 @entity66 @entity1261 @entity229 @entity786 @entity2879 @entity1398 @entity1778 @entity1891 @entity1732 @entity4383 @entity1431 @entity978
The purpose of this prospective phase II trial was to investigate the safety and efficacy of a modified baseline BEACOPP ( @entity1732 , @entity2879 , @entity632 , @entity786 , @entity1891 , @entity4174 , and @entity229 ) regimen in the treatment of intermediate and advanced stage @entity978 ( @entity978 ). From October 1997 to November 2001, 51 consecutive, previously untreated @entity1 with stage IIA (bulky), IIB, III, and IV disease were treated with a modified baseline BEACOPP regimen with the @entity2879 administered i.v. on day 1 and orally at a dose of 100 mg/m2, on days 2 and 3. Each @entity1 was scheduled to receive eight courses of BEACOPP with consolidation radiotherapy to bulky (> or =5 cm) or @entity66 . There were 25 males and 26 females with a median age of 32 yr (16-65 yr); 80.3% of the @entity1 had @entity4383 @entity978 , 41% had bulky disease (> or =5 cm), 10 were in stage IIA (bulky > or =10 cm), 15 in stage IIB, 19 in stage III, and seven in stage IV. Thirty-seven @entity1 (72.5%) achieved a complete response and 17.6% partial response. No significant difference in overall response rate was observed between @entity1 with: (i) 0-2 vs. > or =3 negative prognostic factors, (ii) in stage II vs. stages III/IV, LDH level, and bulky disease. With a median follow up period of 39.5 months, actuarial 3-yr survival rate is 82% and time to progression rate 72.5%. Treatment with this combination was well tolerated. Grades 3 and 4 @entity1431 and @entity1398 occured in 26% and 28% of the @entity1 , respectively, whereas in 16.3% of the @entity1 infection was observed. Support with @entity1261 was given to 59% of the @entity1 . No case of secondary @entity4289 / @entity1778 has been observed. The results of the present study demonstrate that the modified baseline BEACOPP regimen with radiotherapy used in our @entity1 was well tolerated and effective therapy for intermediate and advanced stage @entity978 . Further follow up time is required to evaluate long-term @entity137 .
